Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Zynaxis surprise victim of Lilly cuts
Zynaxis Inc. has became the latest company to come under the ax as Eli Lilly and Co. continues to reevaluate its collaborative programs.
Lilly gave notice that it
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury